Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies-Reference-Cited by-同舟云学术

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

Published:2024-04-24 Issue:6 Volume:24 Page:457-465
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Oluwole Olalekan O.¹^ORCID,Neelapu Sattva S.²,Ray Markqayne D.³,Limbrick-Oldfield Eve H.⁴^ORCID,Wade Sally W.⁵,Kanters Steve⁴^ORCID,Patel Anik R.³,Locke Frederick L.⁶

Affiliation:

1. Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

2. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Kite, A Gilead Company, Santa Monica, CA, USA

4. RainCity Analytics, Vancouver, BC, Canada

5. Wade Outcomes Research & Consulting, Salt Lake City, UT, USA

6. H. Lee Moffitt Cancer Center, Tampa, FL, USA

Funder

Kite Pharma

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2343801

Reference44 articles.

1. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

2. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

4. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study